Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care company Abbott Labs (NYSE:ABT) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Abbott's business, and see what CAPS investors are saying about the stock right now.

Abbott facts

Headquarters (founded)

Abbott Park, Ill. (1888)

Market Cap

$66.73 billion

Industry

Pharmaceuticals

TTM Revenue

$29.48 billion

Management

CEO Miles White (since 1999)
CFO Thomas Freyman (since 2001)

Return on Equity (average, last three years)

20.6%

Dividend Yield

3.9%

Competitors

Merck (NYSE:MRK)
Sanofi-Aventis (NYSE:SNY)

CAPS members bullish on ABT also bullish on

Johnson & Johnson (NYSE:JNJ)
Procter & Gamble (NYSE:PG)

CAPS members bearish on ABT also bearish on

Pfizer (NYSE:PFE)
Bristol-Myers Squibb (NYSE:BMY)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 1,273 of the 1,346 members who have rated Abbott -- some 94.5% -- believe the stock will outperform the S&P 500 going forward. These bulls include bobbyabull and All-Star lemus.

Last month, bobbyabull tapped Abbott as a safe way to make some decent income:

Great addition to a conservative, diversified portfolio at this price. … nice dividend means you get paid to wait for the (inevitable) capital appreciation. After the past 18 months, I like to dollar cost average into stocks that allow me to sleep at night. This is that kind of stock.

In a more recent pitch from last week, lemus follows that bullish line of reasoning:

Great company with a lot of good products. Patents on their drugs are not near expiration, unlike some of their competitors. Nice dividend with a history of increases. I see no reason why this stock deserves to get beaten up as much as it has. Fears about Obama's healthcare reform are overblown.

What do you think about Abbott Labs, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson and Procter & Gamble are Motley Fool Income Investor picks. Pfizer is a choice of Inside Value. The Fool owns shares of Procter & Gamble. The Fool's disclosure policy always gets a perfect score.